|[July 31, 2014]
Catalent, Inc. Announces Pricing of Its Initial Public Offering
SOMERSET, N.J. --(Business Wire)--
Catalent, Inc. ("Catalent"), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced the pricing of its initial
public offering of 42,500,000 shares of its common stock at $20.50 per
share. The shares are expected to begin trading on the New York Stock
Exchange on July 31, 2014 under the ticker symbol "CTLT," and the
offering is expected to close on August 5, 2014, subject to customary
closing conditions. Catalent has granted the underwriters a 30-day
option to purchase up to an additional 6,375,000 at the initial public
Catalent expects to receive net proceeds of approximately $822.7 million
after deducting underwriting discounts and estimated offering expenses,
and intends to use the proceeds to reduce debt.
Morgan Staney, J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co.,
Jefferies and Deutsche Bank Securities are acting as joint bookrunning
managers for the offering. Blackstone Capital Markets, Piper Jaffray,
Raymond James, Wells Fargo (News - Alert) Securities, William Blair and Evercore are
acting as co-managers for the offering.
A registration statement relating to shares of the common stock of
Catalent has been filed with, and declared effective by, the U.S.
Securities and Exchange Commission ("SEC (News - Alert)"). The registration statement
is available on the SEC's website at www.sec.gov
under the registrant's name.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described above, nor
shall there be any sale of such shares of common stock in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
The offering of the shares of common stock will be made only by means of
a prospectus, copies of which may be obtained from Morgan Stanley & Co.
LLC, Attention: Prospectus Department., 180 Varick Street, 2nd Floor,
New York, NY 10014; or from J.P. Morgan, Attention: Prospectus
Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY, 11717 or via telephone: +1 (866) 803-9204.
[ Back To TMCnet.com's Homepage ]